Episode Details

Shadd Dales and Anthony Varrell sit down with Canopy Growth CEO Luc Mongeau to break down the company’s Q1 2025 earnings — and whether this could finally mark the beginning of a true turnaround.Mongeau took the reins in January, and while this wasn’t fully “his quarter,” early signs of change are showing. Adjusted EBITDA losses improved by 60%, and Canopy slashed its debt from $597M to $304M. Revenue remains pressured, but growth in medical cannabis and strength in Claybourne’s infused pre-rolls — now a top-3 product in Canada — are helping rebuild momentum. Mongeau brings a consumer packaged goods (CPG) mindset to the table, focusing on margin recovery, SKU reduction, and the possibility of future M&A activity. This conversation offers rare CEO-level insight into how one of Canada’s most-watched LPs is repositioning in a turbulent market.Also joining the show is Michael Bronstein, President of the American Trade Association for Cannabis and Hemp, to talk about Pennsylvania’s Senate session this week. Could we see a new adult-use cannabis bill proposed? What’s the political climate really like behind the scenes?Find out by clicking here.0:00:00 IntroLuc Mongeau Interview0:01:48 Canopy Growth Strategy0:10:50 Claiborne Pre-Rolls Performance0:12:28 Canadian Cannabis Market Overview0:15:41 Financial Performance Review0:20:53 Canopy USA Market DiscussionInsider's Edge Segment0:25:33 Introduction and start of discussion0:31:31 Pennsylvania Cannabis legalization0:39:08 Medical market in Pennsylvania0:40:25 Texas legislative developments (SB3)0:47:24 Potential scenarios for Texas bill0:56:40 ATACH role and industry insights0:59:26 Wrap up#CanopyGrowth #CannabisStocks #CannabisReform #LucMongeau #MichaelBronstein #PennsylvaniaCannabis #MarijuanaLegalization

Listen Now